resource-symbol

Chronic Treatment Acceptance Questionnaire (ACCEPT)

Mapi

Distributed by Mapi Research Trust

Distributed by Mapi Research Trust

default distrib
 

Basic description

Developed in 2008

Authors

Mapi

Copyright
ACCEPT© Mapi, 2011. All rights reserved.
Objective
The ACCEPT© questionnaire is a generic medication acceptance measure assessing how patients weigh advantages and disadvantages of long-term medications. ACCEPT© may be a predictor of patients' future adherence to and/or persistence with their treatment.
Therapeutic area
  • Generic
Therapeutic indication

All

Chronic diseases requiring long-term medications
Type of Clinical Outcome Assessment (COA)
  • PRO PRO
Original language(s)
  • French for France
Bibliographic reference(s) of the original questionnaire

Arnould B, Gauchoux R, Meunier J, Gilet H, Regnault A. Validation of ACCEPT, a new generic measure to assess how patients with chronic diseases balance between the advantages and disadvantages of following the recommended treatment regimen in real-life. ISPOR 16th Annual European Congress, Dublin, Ireland, November 2013

Marant C, Longin J, Gauchoux R, Arnould B, Spizak C, Marrel A, Patrick DL, Van Ganse E. Long-term treatment acceptance: what is it, and how can it be assessed? Patient. 2012;5(4):239-49 (PubMed Abstract)

Chretin S, Viala-Danten M, Van Ganse E, Patrick D, Arnould B, Longin J. The missing piece between treatment experience and intention to persist: testing the internal consistency reliability and predictive validity of acceptability.  ISPOR 13th Annual European Congress, Prague, Czech Republic, November 2010

Marant C, Longin J, Spizak C, Patrick D, Saussier C, Arnould B, Van Ganse E. What does acceptability mean for patients and how should it be measured? Qualitative steps for the development of a new measurement instrument for pharmacies: the “ACCEPT©” questionnaire. ISPOR 11th Annual European Congress, Athens, Greece, November 2008


Contact and conditions of use

Authors

Mapi

Benoit Arnould
Mapi
27 rue de la Villette
69003 Lyon
France
Email: barnould@mapigroup.com

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Telephone: +33 (0)4 72 13 65 75

Conditions of use

User is required to obtain written permission to use the ACCEPT by contacting the following person:

Benoit Arnould
Mapi
27 rue de la Villette
69003 Lyon
France
Email: barnould@mapigroup.com

Then please follow the steps below:

  1. All requests have to be submitted through our online request management (Tutorials are available on our FAQs)
  2. In order to accelerate the process, you may attach the completed User Agreement (link below) to your online request
  3. Send the user agreement signed hard copy by regular mail to Mapi Research Trust, as we need it for our records
  4. Our PROVIDE team will get back to you with the needed information in a timely manner

Access fees

ROYALTY FEES* Commercial users Cost per study 1 500 €
Cost per language 500 €
Funded academic research Cost per study Free
Cost per language Free
Not funded academic users Cost per study Free
Cost per language Free
DISTRIBUTION FEES* Commercial users Cost per study 700 €
Cost per language 300 €
Funded academic research Cost per study 300 €
Cost per language 50 €
Not funded academic users Cost per study Free
Cost per language Free

* Excluding VAT
Commercial users: Industry, CRO, any for-profit companies
Funded Academic research: Projects receiving funding from commerce, government, EU or registered charity. Funded academic research– sponsored by industry fits the “commercial users” category.
Not funded academic users, individual medical practice: Projects are not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust.

Languages

Original language(s)

  • French for France

Translations

The list of translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.

ACCEPT

English for Canada*
English for the UK*
English for the USA*
French for Canada*
French for Switzerland*
German for Germany*
German for Switzerland*
Italian for Italy*
Portuguese for Brazil*
Russian for Russia*
Slovak for Slovakia*
Spanish for Argentina*
Spanish for Colombia*
Spanish for Mexico*
Spanish for Spain*
Spanish for the USA*
* Performed by Mapi

The author has selected Mapi as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

Please submit a request to sign a translation agreement and to obtain Linguistic Validation Guidelines. To submit a request, please consult our FAQs.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi

Last update: March 2017
For additional information, please submit a request. More information on our FAQs.